C12N 2320/11
For the determination of target sites, i.e. of active nucleic acids
Official title: for the determination of target sites, i.e. of active nucleic acids
C12N2320/11 (For the determination of target sites, i.e. of active nucleic acids) appears on 513 US grants and 1,164 published applications in this corpus.
Search patents in C12N- Granted patents
- 513
- Published applications
- 1,164
- Assignees
- 384
- Inventors
- 1,672
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 4 |
| 2004 | 1 | 9 |
| 2005 | 0 | 23 |
| 2006 | 1 | 23 |
| 2007 | 2 | 70 |
| 2008 | 0 | 64 |
| 2009 | 38 | 51 |
| 2010 | 41 | 57 |
| 2011 | 26 | 37 |
| 2012 | 35 | 57 |
| 2013 | 29 | 38 |
| 2014 | 34 | 49 |
| 2015 | 27 | 39 |
| 2016 | 28 | 35 |
| 2017 | 30 | 37 |
| 2018 | 18 | 38 |
| 2019 | 25 | 47 |
| 2020 | 26 | 37 |
| 2021 | 30 | 53 |
| 2022 | 25 | 79 |
| 2023 | 27 | 97 |
| 2024 | 26 | 96 |
| 2025 | 22 | 68 |
| 2026 | 21 | 55 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Small interfering RNA targeting C3 and uses thereof11 Aug 2026US 12,703,865 B2Sanegene Bio USA Inc.
- Treatment of optic atrophy26 May 2026US 12,637,676 B2PYC Therapeutics Limited
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use19 May 2026US 12,630,826 B2Arrowhead Pharmaceuticals, Inc.
- Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4)12 May 2026US 12,624,396 B2Fred Hutchinson Cancer Center
- Compounds and methods for reducing ATXN3 expression5 May 2026US 12,618,069 B2Ionis Pharmaceuticals, Inc.
- Antisense oligomers for treatment of conditions and diseases17 Sep 2026US 2026/0275346 A1Stoke Therapeutics, Inc.
- Compositions and methods for the treatment of hemoglobinopathies10 Sep 2026US 2026/0265743 A1Intellia Therapeutics, Inc.
- Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof27 Aug 2026US 2026/0248964 A1Intellia Therapeutics, Inc.
- Compositions and methods for epigenetic regulation of pcsk9 expression27 Aug 2026US 2026/0250646 A1Chroma Medicine, Inc.
- Antisense oligonucleotide agents for treating conditions associated with nlrp3/nlrp1 expression or activation27 Aug 2026US 2026/0250685 A1Molecular Axiom, LLC
Most cited
By later US patents
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation451US 8,889,418 B2Massachusetts Institute of Technology · 2014